Pharmion Corporation (Nasdaq: PHRM) announced the submission of a new drug application (NDA) supplement to add IV administration to instructions ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE